These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37978164)

  • 1. A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.
    Hao X; Bao Z; Dai R; Wu X; Li X; Zhang M; Li H; Xu L; Qiao P; Liu X; Hu W; Zhang Z; Fang J; Zhou M; Wang W; Qu J
    Front Med; 2024 Feb; 18(1):169-179. PubMed ID: 37978164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
    Bai Y; Du Z; Wang L; Lau EHY; Fung IC; Holme P; Cowling BJ; Galvani AP; Krug RM; Meyers LA
    Emerg Infect Dis; 2024 Feb; 30(2):262-269. PubMed ID: 38181800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
    Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
    Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
    Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
    Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy.
    Dong R; Huang Y; Ling X; Li L; Yu W; Jiang S
    Int J Antimicrob Agents; 2024 Jan; 63(1):106997. PubMed ID: 37848106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
    Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
    Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
    Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
    Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
    Reina J; Iglesias C
    Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
    Prikis M; Cameron A
    Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
    Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
    Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.
    Buchynskyi M; Oksenych V; Kamyshna I; Kamyshnyi O
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38257811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M
    Catlin NR; Bowman CJ; Campion SN; Cheung JR; Nowland WS; Sathish JG; Stethem CM; Updyke L; Cappon GD
    Reprod Toxicol; 2022 Mar; 108():56-61. PubMed ID: 35101563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.
    Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paxlovid: Mechanism of Action, Synthesis, and
    Marzi M; Vakil MK; Bahmanyar M; Zarenezhad E
    Biomed Res Int; 2022; 2022():7341493. PubMed ID: 35845944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.